CAM2029 (octreotide subcutaneous depot)
CAM2029 is Camurus's monthly octreotide depot that patients can inject themselves, positive in the phase 3 SORENTO trial for gastroenteropancreatic neuroendocrine tumours against the standard depot formulations.
Overview
Camurus of Lund built CAM2029 on its FluidCrystal lipid depot so that octreotide can be given as a small subcutaneous self-injection rather than the intramuscular Sandostatin LAR. The phase 3 SORENTO trial in advanced gastroenteropancreatic neuroendocrine tumours met its primary endpoint of progression-free survival against octreotide LAR or lanreotide, and the company has filed in Europe and the United States; it is approved for acromegaly as Oczyesa in some markets.
Octreotide, a somatostatin analogue, released for a month from a lipid depot that forms under the skin after a small ready-to-use injection. Connects to Somatostatin receptor 2.
1.CAM2029 (octreotide subcutaneous depot) binds Somatostatin receptor 2.
- AmivantamabApproved
- CamizestrantApproved
- Comprehensive genomic profilingStandard of care
- Liquid biopsy (ctDNA)Standard of care
- LorlatinibApproved
- MRD / molecular residual disease testingEstablished
- ADC payload neutralisersPhase 1
- BGB-16673Phase 3
- Bispecific ADCPhase 3
- BRUIN CLL-321Positive
- CaDAnCe-304Recruiting
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- A clone report from blood at every treatment cycle
- A fast route to the matched drug when it is licensed for another cancer
- A multi-cancer platform trial of adaptive (dose-holiday) therapy
- A national rapid research autopsy network for end-stage cancer
- A standard evolvability score for every tumour
- A standing platform trial that assigns treatment by how the tumour escaped
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas · Lines of therapy.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"CAM2029" OR ABSTRACT:"CAM2029" OR TITLE:"octreotide subcutaneous depot" OR ABSTRACT:"octreotide subcutaneous depot") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CAM2029 (octreotide subcutaneous depot), not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentPeluntamig
Shares Neuroendocrine tumours and the tag pipeline.
- TreatmentRezvilutamide
Shares Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
- TreatmentZG006
Shares Neuroendocrine tumours and the tag pipeline.
- TreatmentZanzalintinib
Shares Neuroendocrine tumours and the tag pipeline.
- TreatmentPM8002
Shares Neuroendocrine tumours and the tag pipeline.
- IdeaSSTR antagonist radioligands to increase tumour dose
- TargetDopamine D2 receptor
- CompanyPOINT Biopharma